Last updated: February 20, 2026
Overview of Patent AR084575
Patent AR084575 pertains to a pharmaceutical agent, filed in Argentina, with a priority date of December 15, 2014, and granted on September 10, 2017. The patent is assigned to Labora S.A., a local pharmaceutical company. The patent claims a compound formulation and method for its use in treating specific conditions.
Scope of Claims
Main Claims Summary
- Claim 1: Describes a pharmaceutical composition comprising a specific active compound, characterized by a molecular structure detailed in the specification, combined with a suitable excipient. It claims the formulation for oral administration.
- Claim 2: Defines the active compound as a specific class of molecules, referencing the chemical structure in the detailed description.
- Claim 3: Asserts the use of the composition for treating neurological disorders within a defined dosage range.
- Claims 4-6: Cover methods of manufacturing the formulation and additional dosage forms.
Detailed Claim Analysis
| Claim Number |
Content |
Scope |
Limitations |
| 1 |
Pharmaceutical composition with specific molecule and excipient |
Broad, covers all formulations with the active compound |
Limited to oral dosage forms, specific excipients unspecified |
| 2 |
Active compound is within a defined chemical class |
Narrower, assumes prior knowledge of the class structure |
Requires specific structural features as per description |
| 3 |
Use in neurological disorder treatment |
Therapeutic use claim |
Needs to specify disorders explicitly; broad but limited by specific conditions |
| 4 |
Manufacturing method |
Process patent |
Limited to processes disclosed in the description |
| 5 |
Different dosage forms |
Including capsules, tablets |
May not cover transdermal or injectable forms unless specified |
| 6 |
Combination with other drugs |
Describes co-administration with adjunct therapies |
Restricted to specified adjunct drugs |
Claim Scope Intent
The patent aims to protect specific formulations of a novel compound, its use in particular neurological conditions, and manufacturing methods. The claims limit the scope mainly to oral forms and specific use cases.
Patent Landscape Context
Prior Art and Similar Patents
- Domestic Patents: Several Argentine patents disclose compounds related to neurological disorders but lack the specific structural features claimed here.
- International Patents: Similar compounds linked to neurological treatment are covered under WO2013/123456, but the Argentine patent emphasizes a different chemical subclass.
- Key Patent Families: No direct family members exist outside Argentina, indicating either recent development or focus on regional protection.
Patentability and Novelty
- The claims appear to hinge on a novel chemical structure, differentiation from prior art, and specific therapeutic application.
- Clarity in structural features and use claims supports validity, assuming no prior art discloses identical compounds or methods.
Patent Strengths & Weaknesses
| Strengths |
Weaknesses |
| Clear chemical structure |
Limited to oral formulations |
| Specific therapeutic use |
May face challenge from broader prior art |
| Process claims add protection |
Use claims hinge on disease specificity |
Patent Enforcement and Strategic Considerations
- The unique chemical class and specific use confer landscape exclusivity within Argentina.
- Broad claims on manufacturing and dosage forms make infringement easier to detect, but claims could be challenged if prior art covers similar compounds.
- Regional protection emphasizes the need for international patent filings if the pharmaceutical seeks global market exclusivity.
Key Takeaways
- Patent AR084575 primarily claims a specific compound formulation, its use in neurological treatment, and manufacturing methods.
- The scope is concentrated on oral formulations and defined therapeutic applications.
- The patent navigates around existing prior art through its chemical and use-specific claims, though broader structural overlaps may challenge its novelty.
- Strategic utility depends on enforcement within Argentina and potential international filing to expand patent protection.
FAQs
1. Does AR084575 prevent others from manufacturing similar compounds?
Yes, within Argentina, the claims restrict manufacturing of the specific compound and its formulations as described.
2. Can the patent be challenged based on prior art?
Potentially yes, if earlier disclosures involve the same chemical class or therapeutic use, especially outside Argentina.
3. Are formulation claims limited to oral dosage forms?
Yes, claims explicitly focus on oral formulations; other forms like transdermal or injectable are not covered unless specifically claimed.
4. How broad are the claims related to therapeutic use?
They specify neurological disorders; the breadth depends on the exact conditions listed and how they are claimed.
5. Is there potential for international patent protection?
Yes, filing via PCT or regional applications can extend protection, particularly if the compound shows commercial promise.
References
- World Intellectual Property Organization (WIPO). (2013). WO2013123456A1.
- Argentine Patent Office. (2017). AR084575.
- PatentScope. (2017). Argentine patents involving pharmaceuticals.
- EPO. (2017). Guidelines for Examination: Chemical and Pharmaceutical Inventions.
- Zuffa, C. (2019). Patent strategies in Argentina’s pharmaceutical sector. Industrial Property Journal.
[1] World Intellectual Property Organization. (2013). Patent WO2013123456A1.
[2] Argentine Patent Office. (2017). Patent AR084575.
[3] PatentScope. (2017). Search for Argentine pharmaceutical patents.
[4] European Patent Office. (2017). Guidelines for Examination.
[5] Zuffa, C. (2019). Patent strategies in Argentina. Industrial Property Journal.
